Personal information

Emails & domains

Verified email domains

Other IDs

Scopus Author ID: 8791558200

Countries

United Kingdom

Activities

Collapse all

Employment (1)

University of Glasgow School of Medicine Dentistry and Nursing: Glasgow, Glasgow, GB

2010-02-10 to present | Professor of Breast Oncology (School of Cancer Sciences )
Employment
Source: Self-asserted source
Iain Macpherson

Funding (7)

CESAR: Contrast Enhanced mammography versus magnetic reSonace imaging for Assessing Response to neoadjuvant chemotherapy

2024-09-01 to 2027-08-31 | Grant
National Institute for Health and Care Research (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.14040731
GRANT_NUMBER: NIHR156766
Source: Self-asserted source
Iain Macpherson via DimensionsWizard

The HER2-RADiCAL study (Response ADaptive CAre pLan) - tailoring treatment for HER2 positive early breast cancer

2021-06-01 to 2029-11-30 | Grant
NIHR Evaluation Trials and Studies Coordinating Centre (Southampton, GB)
URL: https://app.dimensions.ai/details/grant/grant.9959332
GRANT_NUMBER: NIHR131362
Source: Self-asserted source
Iain Macpherson via DimensionsWizard

Evaluation of metabotropic glutamate receptor 3 as a therapeutic target in breast cancer

2019-08-01 to 2022-07-31 | Grant
Breast Cancer Now (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.8483100
GRANT_NUMBER:

2018NovPR1268
Source: Self-asserted source
Iain Macpherson via DimensionsWizard

NEPTUNE: Enhancement of immuNothEraPy combining avelUmab and repeaT doses of radiUm-223 in ER+ve, HER2-ve metastatic breast caNcEr.

2019-07-01 to 2023-02-28 | Grant
Breast Cancer Now (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.7920940
GRANT_NUMBER:

2017NovCC1073
Source: Self-asserted source
Iain Macpherson via DimensionsWizard

Phase Ib Study of Palbociclib and Avelumab in Metastatic AR+ triple negative breast cancer

2018-10-01 to 2021-09-30 | Grant
Breast Cancer Now (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.7920939
GRANT_NUMBER:

2017NovCC1080
Source: Self-asserted source
Iain Macpherson via DimensionsWizard

Stretching the supply routes: ErbB2 gene amplification and endocytic recycling in metastatic breast cancer

2015-01-15 to 2019-01-14 | Grant
Breast Cancer Now (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.7388627
GRANT_NUMBER:

2014MayPR292
Source: Self-asserted source
Iain Macpherson via DimensionsWizard

Rab-coupling protein (RCP)-mediated receptor trafficking in breast cancer progression.

2013-01-07 to 2016-01-06 | Grant
Breast Cancer Now (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.5140825
GRANT_NUMBER:

2011NovPR12
Source: Self-asserted source
Iain Macpherson via DimensionsWizard

Works (50 of 157)

Items per page:
Page 1 of 4

The impact of symptom clusters on endocrine therapy adherence in patients with breast cancer

The Breast
2024-06 | Journal article
DOI: 10.1016/j.breast.2024.103731
Contributors: Sommer Agnew; Megan Crawford; Iain MacPherson; Victor Shiramizu; Leanne Fleming
Source: check_circle
Crossref

Data from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.c.7065316
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Data from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.c.7065316.v1
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer

Cancer Discovery
2024-02-08 | Journal article
DOI: 10.1158/2159-8290.CD-22-1387
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Figure 1 from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25183894.v1
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Figure 1 from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25183894
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Figure 2 from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25183891
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Figure 2 from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25183891.v1
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Figure 3 from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25183888
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Figure 3 from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25183888.v1
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Figure 4 from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25183885
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Figure 4 from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25183885.v1
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Figure 5 from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25183882.v1
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Figure 5 from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25183882
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Figure 6 from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25183879
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Figure 6 from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25183879.v1
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Supplementary Figures 1-9 from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25183876
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Supplementary Figures 1-9 from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25183876.v1
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Supplementary Figures 1-9 from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25191450
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Supplementary Figures 1-9 from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25191450.v1
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Supplementary Methods from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25183873
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Supplementary Methods from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25183873.v1
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Supplementary Methods from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25191447
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Supplementary Methods from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25191447.v1
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Supplementary Tables 1-2 from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25183870
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Supplementary Tables 1-2 from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25183870.v1
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Supplementary Tables 1-2 from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25191444
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Supplementary Tables 1-2 from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25191444.v1
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Table 1 from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25183867.v1
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Table 1 from <i>ESR1</i> F404 Mutations and Acquired Resistance to Fulvestrant in <i>ESR1</i>-Mutant Breast Cancer

2024-02-08 | Preprint
DOI: 10.1158/2159-8290.25183867
Contributors: Belinda Kingston; Alex Pearson; Maria Teresa Herrera-Abreu; Li-Xuan Sim; Rosalind J. Cutts; Heena Shah; Laura Moretti; Lucy S. Kilburn; Hannah Johnson; Iain R. Macpherson et al.
Source: check_circle
Crossref

Data from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

2023-12-01 | Preprint
DOI: 10.1158/1078-0432.c.6960638
Contributors: Alistair Ring; Lucy S. Kilburn; Alex Pearson; Laura Moretti; Angelica Afshari-Mehr; Andrew M. Wardley; Bora Gurel; Iain R. Macpherson; Ruth Riisnaes; Richard D. Baird et al.
Source: check_circle
Crossref

Data from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

2023-12-01 | Preprint
DOI: 10.1158/1078-0432.c.6960638.v1
Contributors: Alistair Ring; Lucy S. Kilburn; Alex Pearson; Laura Moretti; Angelica Afshari-Mehr; Andrew M. Wardley; Bora Gurel; Iain R. Macpherson; Ruth Riisnaes; Richard D. Baird et al.
Source: check_circle
Crossref

Figure 1 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

2023-12-01 | Preprint
DOI: 10.1158/1078-0432.24710765
Contributors: Alistair Ring; Lucy S. Kilburn; Alex Pearson; Laura Moretti; Angelica Afshari-Mehr; Andrew M. Wardley; Bora Gurel; Iain R. Macpherson; Ruth Riisnaes; Richard D. Baird et al.
Source: check_circle
Crossref

Figure 1 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

2023-12-01 | Preprint
DOI: 10.1158/1078-0432.24710765.v1
Contributors: Alistair Ring; Lucy S. Kilburn; Alex Pearson; Laura Moretti; Angelica Afshari-Mehr; Andrew M. Wardley; Bora Gurel; Iain R. Macpherson; Ruth Riisnaes; Richard D. Baird et al.
Source: check_circle
Crossref

Figure 2 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

2023-12-01 | Preprint
DOI: 10.1158/1078-0432.24710762
Contributors: Alistair Ring; Lucy S. Kilburn; Alex Pearson; Laura Moretti; Angelica Afshari-Mehr; Andrew M. Wardley; Bora Gurel; Iain R. Macpherson; Ruth Riisnaes; Richard D. Baird et al.
Source: check_circle
Crossref

Figure 2 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

2023-12-01 | Preprint
DOI: 10.1158/1078-0432.24710762.v1
Contributors: Alistair Ring; Lucy S. Kilburn; Alex Pearson; Laura Moretti; Angelica Afshari-Mehr; Andrew M. Wardley; Bora Gurel; Iain R. Macpherson; Ruth Riisnaes; Richard D. Baird et al.
Source: check_circle
Crossref

Figure 3 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

2023-12-01 | Preprint
DOI: 10.1158/1078-0432.24710759.v1
Contributors: Alistair Ring; Lucy S. Kilburn; Alex Pearson; Laura Moretti; Angelica Afshari-Mehr; Andrew M. Wardley; Bora Gurel; Iain R. Macpherson; Ruth Riisnaes; Richard D. Baird et al.
Source: check_circle
Crossref

Figure 3 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

2023-12-01 | Preprint
DOI: 10.1158/1078-0432.24710759
Contributors: Alistair Ring; Lucy S. Kilburn; Alex Pearson; Laura Moretti; Angelica Afshari-Mehr; Andrew M. Wardley; Bora Gurel; Iain R. Macpherson; Ruth Riisnaes; Richard D. Baird et al.
Source: check_circle
Crossref

Figure 4 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

2023-12-01 | Preprint
DOI: 10.1158/1078-0432.24710756
Contributors: Alistair Ring; Lucy S. Kilburn; Alex Pearson; Laura Moretti; Angelica Afshari-Mehr; Andrew M. Wardley; Bora Gurel; Iain R. Macpherson; Ruth Riisnaes; Richard D. Baird et al.
Source: check_circle
Crossref

Figure 4 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

2023-12-01 | Preprint
DOI: 10.1158/1078-0432.24710756.v1
Contributors: Alistair Ring; Lucy S. Kilburn; Alex Pearson; Laura Moretti; Angelica Afshari-Mehr; Andrew M. Wardley; Bora Gurel; Iain R. Macpherson; Ruth Riisnaes; Richard D. Baird et al.
Source: check_circle
Crossref

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Clinical Cancer Research
2023-12-01 | Journal article
DOI: 10.1158/1078-0432.CCR-23-1696
Contributors: Alistair Ring; Lucy S. Kilburn; Alex Pearson; Laura Moretti; Angelica Afshari-Mehr; Andrew M. Wardley; Bora Gurel; Iain R. Macpherson; Ruth Riisnaes; Richard D. Baird et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

2023-12-01 | Preprint
DOI: 10.1158/1078-0432.24710753
Contributors: Alistair Ring; Lucy S. Kilburn; Alex Pearson; Laura Moretti; Angelica Afshari-Mehr; Andrew M. Wardley; Bora Gurel; Iain R. Macpherson; Ruth Riisnaes; Richard D. Baird et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

2023-12-01 | Preprint
DOI: 10.1158/1078-0432.24710753.v1
Contributors: Alistair Ring; Lucy S. Kilburn; Alex Pearson; Laura Moretti; Angelica Afshari-Mehr; Andrew M. Wardley; Bora Gurel; Iain R. Macpherson; Ruth Riisnaes; Richard D. Baird et al.
Source: check_circle
Crossref

Supplementary Figure S2 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

2023-12-01 | Preprint
DOI: 10.1158/1078-0432.24710750
Contributors: Alistair Ring; Lucy S. Kilburn; Alex Pearson; Laura Moretti; Angelica Afshari-Mehr; Andrew M. Wardley; Bora Gurel; Iain R. Macpherson; Ruth Riisnaes; Richard D. Baird et al.
Source: check_circle
Crossref

Supplementary Figure S2 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

2023-12-01 | Preprint
DOI: 10.1158/1078-0432.24710750.v1
Contributors: Alistair Ring; Lucy S. Kilburn; Alex Pearson; Laura Moretti; Angelica Afshari-Mehr; Andrew M. Wardley; Bora Gurel; Iain R. Macpherson; Ruth Riisnaes; Richard D. Baird et al.
Source: check_circle
Crossref

Supplementary Figure S3 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

2023-12-01 | Preprint
DOI: 10.1158/1078-0432.24710747
Contributors: Alistair Ring; Lucy S. Kilburn; Alex Pearson; Laura Moretti; Angelica Afshari-Mehr; Andrew M. Wardley; Bora Gurel; Iain R. Macpherson; Ruth Riisnaes; Richard D. Baird et al.
Source: check_circle
Crossref

Supplementary Figure S3 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

2023-12-01 | Preprint
DOI: 10.1158/1078-0432.24710747.v1
Contributors: Alistair Ring; Lucy S. Kilburn; Alex Pearson; Laura Moretti; Angelica Afshari-Mehr; Andrew M. Wardley; Bora Gurel; Iain R. Macpherson; Ruth Riisnaes; Richard D. Baird et al.
Source: check_circle
Crossref

Supplementary Table S1 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

2023-12-01 | Preprint
DOI: 10.1158/1078-0432.24710744.v1
Contributors: Alistair Ring; Lucy S. Kilburn; Alex Pearson; Laura Moretti; Angelica Afshari-Mehr; Andrew M. Wardley; Bora Gurel; Iain R. Macpherson; Ruth Riisnaes; Richard D. Baird et al.
Source: check_circle
Crossref

Supplementary Table S1 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

2023-12-01 | Preprint
DOI: 10.1158/1078-0432.24710744
Contributors: Alistair Ring; Lucy S. Kilburn; Alex Pearson; Laura Moretti; Angelica Afshari-Mehr; Andrew M. Wardley; Bora Gurel; Iain R. Macpherson; Ruth Riisnaes; Richard D. Baird et al.
Source: check_circle
Crossref

Supplementary Table S2 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

2023-12-01 | Preprint
DOI: 10.1158/1078-0432.24710741
Contributors: Alistair Ring; Lucy S. Kilburn; Alex Pearson; Laura Moretti; Angelica Afshari-Mehr; Andrew M. Wardley; Bora Gurel; Iain R. Macpherson; Ruth Riisnaes; Richard D. Baird et al.
Source: check_circle
Crossref
Items per page:
Page 1 of 4

Peer review (2 reviews for 2 publications/grants)

Review activity for Breast cancer research and treatment. (1)
Review activity for British journal of cancer. (1)
How many people are using ORCID?